Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas

Journal of Immunology

Volumn 192, Issue 1, 2014, Pages 512-522

  Hamilton, Melisa J ^a   Bosiljcic, Momir ^a   LePard, Nancy E ^a   Halvorsen, Elizabeth C ^a   Ho, Victor W ^b   Banáth, Judit P ^a   Krystal, Gerald ^b   Bennewith, Kevin L ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; BREAST METASTASIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LUNG PARENCHYMA; MACROPHAGE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; TARGET CELL; TARGET ORGAN; TUMOR DIFFERENTIATION;

EID: 84891059452     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300096     Document Type: Article

References (50)

1. Youn, J. I., and D. I. Gabrilovich. 2010. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40: 2969-2975.
2. Qian, B. Z., and J. W. Pollard. 2010. Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
3. Siveen, K. S., and G. Kuttan. 2009. Role of macrophages in tumour progression. Immunol. Lett. 123: 97-102.
4. Mantovani, A., and A. Sica. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22: 231-237.
5. Erler, J. T., K. L. Bennewith, T. R. Cox, G. Lang, D. Bird, A. Koong, Q. T. Le, and A. J. Giaccia. 2009. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15: 35-44.
6. Nagaraj, S., and D. I. Gabrilovich. 2010. Myeloid-derived suppressor cells in human cancer. Cancer J. 16: 348-353.
7. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
8. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.
9. Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
10. Montero, A. J., C. M. Diaz-Montero, C. E. Kyriakopoulos, V. Bronte, and S. Mandruzzato. 2012. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 35: 107-115.
11. Guth, A. M., W. J. Janssen, C. M. Bosio, E. C. Crouch, P. M. Henson, and S. W. Dow. 2009. Lung environment determines unique phenotype of alveolar macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 296: L936-L946.
12. Leek, R. D., C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, and A. L. Harris. 1996. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56: 4625-4629.
13. Qian, B., and Y. Deng. J. H. Im, R. J. Muschel, Y. Zou, J. Li, R. A. Lang, and J.W. Pollard. 2009. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4: e6562.
14. Kusmartsev, S., F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63: 4441-4449.
15. Kusmartsev, S., Z. Su, A. Heiser, J. Dannull, E. Eruslanov, H. Kübler, D. Yancey, P. Dahm, and J. Vieweg. 2008. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14: 8270-8278.
16. Mirza, N., M. Fishman, I. Fricke, M. Dunn, A. M. Neuger, T. J. Frost, R. M. Lush, S. Antonia, and D. I. Gabrilovich. 2006. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66: 9299-9307.
17. Lathers, D. M., J. I. Clark, N. J. Achille, and M. R. Young. 2004. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol. Immunother. 53: 422-430.
18. Steeg, P. S. 2006. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12: 895-904.
19. Kaplan, R. N., R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent, C. Costa, D. D. MacDonald, D. K. Jin, K. Shido, S. A. Kerns, et al. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
20. Murphy, K. M., A. B. Heimberger, and D. Y. Loh. 1990. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250: 1720-1723.
21. Guy, C. T., R. D. Cardiff, and W. J. Muller. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12: 954-961.
22. Dexter, D. L., H. M. Kowalski, B. A. Blazar, Z. Fligiel, R. Vogel, and G. H. Heppner. 1978. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 38: 3174-3181.
23. Hamilton, M. J., J. P. Banáth, V. Lam, N. E. Lepard, G. Krystal, and K. L. Bennewith. 2012. Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice. Cancer Immunol. Immunother. 61: 643-654.
24. Rauh, M. J., V. Ho, C. Pereira, A. Sham, L. M. Sly, V. Lam, L. Huxham, A. I. Minchinton, A. Mui, and G. Krystal. 2005. SHIP represses the generation of alternatively activated macrophages. Immunity 23: 361-374.
25. Hamilton, M. J., F. Antignano, A. von Rossum, J. L. Boucher, K. L. Bennewith, and G. Krystal. 2010. TLR agonists that induce IFN-beta abrogate resident macrophage suppression of T cells. J. Immunol. 185: 4545-4553.
26. Gallina, G., L. Dolcetti, P. Serafini, C. De Santo, I. Marigo, M. P. Colombo, G. Basso, F. Brombacher, I. Borrello, P. Zanovello, et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116: 2777-2790.
27. Richards, D. M., J. Hettinger, and M. Feuerer. 2013. Monocytes and macrophages in cancer: development and functions. Cancer Microenviron. 6: 179-191.
28. Pulaski, B. A., and S. Ostrand-Rosenberg. 2001. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. Chapter 20: Unit 20.2.
29. Gabrilovich, D. I., S. Ostrand-Rosenberg, and V. Bronte. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12: 253-268.
30. Bastien, J., and C. Rochette-Egly. 2004. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 328: 1-16.
31. Nefedova, Y., M. Fishman, S. Sherman, X. Wang, A. A. Beg, and D. I. Gabrilovich. 2007. Mechanism of all-trans retinoic acid effect on tumorassociated myeloid-derived suppressor cells. Cancer Res. 67: 11021-11028.
32. Schulz, C., E. Gomez Perdiguero, L. Chorro, H. Szabo-Rogers, N. Cagnard, K. Kierdorf, M. Prinz, B. Wu, S. E. Jacobsen, J. W. Pollard, et al. 2012. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336: 86-90.
33. Gordon, S. 2003. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35.
34. Cuenca, A. G., M. J. Delano, K. M. Kelly-Scumpia, C. Moreno, P. O. Scumpia, D. M. Laface, P. G. Heyworth, P. A. Efron, and L. L. Moldawer. 2011. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17: 281-292.
35. Dolcetti, L., E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez Gomez, C. Mesa, M. Geilich, G. Winkels, E. Traggiai, A. Casati, et al. 2010. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40: 22-35.
36. Zhang, F., S. S. Lau, and T. J. Monks. 2011. The cytoprotective effect of Nacetyl-L-cysteine against ROS-induced cytotoxicity is independent of its ability to enhance glutathione synthesis. Toxicol. Sci. 120: 87-97.
37. Srivastava, M. K., P. Sinha, V. K. Clements, P. Rodriguez, and S. Ostrand-Rosenberg. 2010. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70: 68-77.
38. Pompella, A., A. Visvikis, A. Paolicchi, V. De Tata, and A. F. Casini. 2003. The changing faces of glutathione, a cellular protagonist. Biochem. Pharmacol. 66: 1499-1503.
39. Almand, B., J. I. Clark, E. Nikitina, J. van Beynen, N. R. English, S. C. Knight, D. P. Carbone, and D. I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166: 678-689.
40. Gabrilovich, D. I., M. P. Velders, E. M. Sotomayor, and W. M. Kast. 2001. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166: 5398-5406.
41. Kusmartsev, S., Y. Nefedova, D. Yoder, and D. I. Gabrilovich. 2004. Antigenspecific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172: 989-999.
42. Kusmartsev, S., and D. I. Gabrilovich. 2003. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74: 186-196.
43. Sanz, M. A., and F. Lo-Coco. 2011. Modern approaches to treating acute promyelocytic leukemia. J. Clin. Oncol. 29: 495-503.
44. Mucida, D., Y. Park, G. Kim, O. Turovskaya, I. Scott, M. Kronenberg, and H. Cheroutre. 2007. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317: 256-260.
45. Ko, J. S., A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. Rayman, L. Wood, J. Garcia, et al. 2009. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15: 2148-2157.
46. Serafini, P., K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203: 2691-2702.
47. Pande, K., R. Ueda, T. Machemer, M. Sathe, V. Tsai, E. Brin, M. J. Delano, N. Van Rooijen, T. K. McClanahan, J. E. Talmadge, et al. 2009. Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviraltriggered anaphylactoid-type reactions. Mol. Ther. 17: 508-515.
48. Lepique, A. P., K. R. Daghastanli, I. M. Cuccovia, and L. L. Villa. 2009. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin. Cancer Res. 15: 4391-4400.
49. Rogers, T. L., and I. Holen. 2011. Tumour macrophages as potential targets of bisphosphonates. J. Transl. Med. 9: 177.
50. Srivastava, M. K., L. Zhu, M. Harris-White, U. K. Kar, M. Huang, M. F. Johnson, J. M. Lee, D. Elashoff, R. Strieter, S. Dubinett, and S. Sharma. 2012. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. [Published erratum appears in 2012 PLoS One. 7(10).] PLoS One 7: e40677.